Category Archives: Global News Feed

NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer’s disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug’s mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (CSF). The posters will be presented at the Alzheimer’s Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28-Aug. 1, 2024.

Read the original:
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International...

All dollar amounts reflected in Canadian dollars unless otherwise stated. All dollar amounts reflected in Canadian dollars unless otherwise stated.

The rest is here:
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement

Wnt-activated, autologous, expanded, adipose-derived stem cells administered directly into lateral ventricles of the brain via Ommaya reservoir implanted under the scalp to bypass blood brain barrier

Excerpt from:
Regeneration Biomedical to Present Data on First Two Subjects in a Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brains of...

– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease –

More:
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s...

Châtillon, France, July 29, 2024

Read more here:
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation.

The rest is here:
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

Boehringer Ingelheim today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of a new indication of SPEVIGO® (spesolimab) injection for the prevention of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age; and extension of the approved indication for SPEVIGO® (spesolimab) infusion for the treatment of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy. SPEVIGO® is a novel, humanized selective IgG1 antibody that binds to interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

Link:
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

SYDNEY, July 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to report promising results from its latest study on the efficacy of RECCE® 327 (R327) against multidrug- resistant (MDR) World Health Organization (WHO) priority pathogen Acinetobacter baumannii (A. baumannii). The study was conducted at Recce’s Anti-Infective Research (AIR) unit within Murdoch Children’s Research Institute.

See more here:
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results.

See the original post here:
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from autoimmune and inflammatory disorders TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from autoimmune and inflammatory disorders

See the article here:
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy